Neoadjuvant chemotherapy for invasive bladder cancer

Results of clinical trial of neoadjuvant chemotherapy with combination of gemcitabine and cisplatin (GC) in comparison with conventional treatment schedule MVAC/CMV (cisplatin, methotrexate, vinblastin ± doxorubicin) for 231 patients with invasive transient cell bladder carcinoma have been presented. Survival, treatment efficacy and toxicity have been studied. The GC schedule has been found to have more moderate and predictable toxicity as compared to the standard chemotherapy schedules (MVAC/CMV).